Last reviewed · How we verify
Olaptesed pegol - Monotherapy — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Olaptesed pegol - Monotherapy (Olaptesed pegol - Monotherapy) — TME Pharma AG.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Olaptesed pegol - Monotherapy TARGET | Olaptesed pegol - Monotherapy | TME Pharma AG | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Olaptesed pegol - Monotherapy CI watch — RSS
- Olaptesed pegol - Monotherapy CI watch — Atom
- Olaptesed pegol - Monotherapy CI watch — JSON
- Olaptesed pegol - Monotherapy alone — RSS
Cite this brief
Drug Landscape (2026). Olaptesed pegol - Monotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/olaptesed-pegol-monotherapy. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing